Fentanyl

• Severe Chronic Pain
• Cancer Pain
• Breakthrough Pain
• Anesthesia

Fentanyl is a potent synthetic opioid analgesic used for the management of severe pain, including cancer pain and breakthrough pain in opioid-tolerant patients, as well as for anesthesia. This medication is approximately 100 times more potent than morphine and requires careful dosing and patient selection due to significant risks including fatal respiratory depression.

Mechanism of Action

Fentanyl is a full agonist at mu-opioid receptors, with some activity at kappa and delta receptors. Binding to mu-opioid receptors in the central nervous system produces analgesia, euphoria, respiratory depression, and physical dependence. The drug's high lipophilicity allows rapid penetration of the blood-brain barrier, producing faster onset of action compared to less lipophilic opioids. Fentanyl also binds to opioid receptors in the spinal cord and peripheral tissues, contributing to its analgesic effects. The rapid onset and short duration of IV fentanyl make it ideal for procedural analgesia and anesthesia.

Available Formulations

Fentanyl is available in numerous formulations for different routes and indications: transdermal patches (12, 25, 50, 75, 100 mcg/hour), transmucosal lozenge (oral transmucosal fentanyl citrate), buccal tablet, buccal film, nasal spray, sublingual tablet, sublingual spray, and injection. Each formulation has specific approved indications and is not interchangeable. Transdermal patches are for chronic pain; transmucosal formulations are specifically for breakthrough cancer pain in opioid-tolerant patients.

Medical Uses

Fentanyl injection is used for perioperative analgesia and as a supplement to anesthesia. Transdermal fentanyl is indicated for management of pain in opioid-tolerant patients severe enough to require daily, around-the-clock opioid treatment. Transmucosal fentanyl products (TIRF - Transmucosal Immediate-Release Fentanyl) are indicated only for breakthrough cancer pain in opioid-tolerant cancer patients already receiving and tolerant to around-the-clock opioid therapy.

Dosing Guidelines

Dosing varies significantly by formulation and indication. For transdermal patches, conversion from prior opioid therapy is required; patches are applied every 72 hours. For breakthrough pain products, dosing starts at the lowest available dose regardless of maintenance opioid dose, with careful titration. Injectable fentanyl doses for analgesia range from 25-100 mcg IV; anesthetic doses are much higher. Only patients receiving at least 60 mg oral morphine equivalents daily for at least 1 week are considered opioid-tolerant for fentanyl initiation.

Important Safety Information

Fentanyl carries a boxed warning for life-threatening respiratory depression, particularly during initiation and dose increases; accidental exposure can cause fatal overdose (especially in children); serious risks from concomitant use with benzodiazepines or CNS depressants; neonatal opioid withdrawal syndrome; and addiction, abuse, and misuse potential. TIRF products are available only through a restricted program (TIRF REMS). Transdermal patches can cause fatal overdose if heat is applied or in febrile patients. Naloxone should be available for emergency reversal.

Drug Interactions

Concomitant use with benzodiazepines, other CNS depressants, or alcohol can cause profound sedation, respiratory depression, coma, and death. CYP3A4 inhibitors (ritonavir, ketoconazole, erythromycin, grapefruit juice) increase fentanyl levels and may cause fatal respiratory depression. CYP3A4 inducers may decrease efficacy. Serotonergic drugs may cause serotonin syndrome. MAO inhibitors are contraindicated (or require washout period).

Where Fentanyl Sits in a Chronic Pain Plan

Transdermal fentanyl is a late option, not a starting one. It is reached for in a narrow group: a patient already taking around-the-clock opioids at a meaningful daily dose, whose pain is continuous rather than intermittent, and for whom an oral route is unreliable or intolerable — difficulty swallowing, persistent nausea and vomiting, malabsorption, or a bowel obstruction. In those circumstances it may be used for severe persistent pain from advanced malignancy, from chronic low back pain that has failed every other approach, or from post-herpetic neuralgia (PHN) of a severity that oral therapy has not controlled. It is never the first opioid, never used for acute injury, postoperative pain, or headache, and never started in a patient who is not already opioid-tolerant.

Before a patch is considered, the non-opioid layers of the plan are expected to be in place and optimized: physical therapy and graded activity, a neuropathic agent such as gabapentin, pregabalin, or duloxetine where the pain is nerve-related, topical therapy, treatment of depression and insomnia, and interventional options where anatomy supports them. Our article on managing chronic pain without opioids covers that groundwork. When an opioid is genuinely needed, an oral agent such as morphine or oxycodone is easier to titrate and easier to stop, and conversion to a patch is considered only once a stable daily requirement is known.

The Safety Practices That Prevent Harm

Three properties of this drug account for most of the serious events reported with it. The patch is a depot: drug continues to be absorbed from the skin for many hours after removal, so an overdose does not resolve when the patch comes off, and a naloxone reversal can wear off before the fentanyl does. Absorption is temperature-dependent, so fever, heating pads, electric blankets, hot tubs, saunas, and prolonged sun exposure can all increase delivery from a patch that has been safe for weeks. And the amount of drug remaining in a used patch is still enough to kill a child or a pet, which is why used patches are folded adhesive-side together and disposed of immediately rather than left in an open trash can.

The counseling that follows from this is specific. One patch at a time unless a prescriber has directed otherwise; never cut, trim, or fold a patch to adjust the dose; apply to intact, unbroken, non-irritated skin and rotate the site; do not shave the area, since razor abrasion changes absorption. Every household is given naloxone and shown how to use it, and family members are told what excessive sedation looks like, because the person on the medication will not be the one who notices. Alcohol, benzodiazepines, sleep medications, and other sedatives multiply the respiratory risk. Storage is locked. The MedlinePlus fentanyl transdermal patch monograph sets out these handling rules in patient language, and the National Institute on Drug Abuse overview of fentanyl explains why the potency of this molecule makes small errors consequential. Patients who develop problematic use of opioids are not failures of character and are not simply tapered and discharged; they are referred for treatment, where buprenorphine and structured support have the best evidence.

Special Populations

Fentanyl use during pregnancy can cause neonatal opioid withdrawal syndrome; chronic use should be avoided if possible. It is excreted in breast milk; breastfeeding is not recommended. Safety and efficacy of transdermal fentanyl have not been established in pediatric patients under 2 years; TIRF products are not for pediatric use. Elderly patients may be more sensitive and should start at lower doses. Dose reduction is needed in hepatic impairment. Renal impairment may increase sensitivity; use with caution.